Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870956 · ClinicalTrials.gov registry record
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,798
- Enrollment target
NCT05870956 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,798 participants.
The verdict
NCT05870956 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,798 participants
- Enrollment target
Study Summary
This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2. To assess the association between a patient's nintedanib adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,798 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05870956
The ClinicalTrials.gov registry entry for NCT05870956 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,798 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT05870956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05870956 about?
NCT05870956 is a clinical study titled "Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients". This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2....
What is the current status of trial NCT05870956?
This trial is currently completed. The enrollment target is 1,798 participants. The study started on 2023-05-16. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05870956?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT05870956?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.